Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

Importance Measurable residual disease (MRD) refers to neoplastic cells that cannot be
detected by standard cytomorphologic analysis. In patients with acute myeloid leukemia …

The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose
cytarabine represents an important new therapy for older or unfit patients with acute myeloid …

The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in
the past few years, driven largely by translational research into its genomic landscape and …

Purpose CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin
that delivers a synergistic 5: 1 drug ratio into leukemia cells to a greater extent than normal …

For several decades, few substantial therapeutic advances have been made for patients
with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen …

Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin …

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults
and accounts for the largest number of annual deaths due to leukemias in the United States …

The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …

Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clinical efficacy in
relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however …